Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

The Effects of Maternal Metformin Treatment on Late Prenatal and Early Postnatal Development of the Offspring Are Modulated by Sex

  • Garcia-Contreras, Consolacion
  • Vázquez-Gómez, M.
  • Pesántez-Pacheco, José Luis
  • Heras-Molina, Ana
  • Encinas, Teresa
  • Astiz, Susana
  • González De Bulnes, Antonio
11 Pág., Metformin is currently used to improve pregnancy outcome in women affected by polycystic ovary syndrome (PCOS) or diabetes. However, metformin may also be useful in pregnancies at risk of intrauterine growth restriction (IUGR) since it improves placental efficiency and the fetuses' developmental competence. There is no data on the duration of the effect of this treatment from the prenatal up to the postnatal stages. Therefore, the present trial aimed at determining the impact of metformin treatment on the offspring neonatal traits and early postnatal development (i.e., during lactation) using an in vivo swine model. The results support that maternal metformin treatment during pregnancy induces protective changes in body shape and composition of the progeny (i.e., larger head size and body length at birth and higher total viscera weight at weaning). However, there were also major effects of the offspring sex (smaller corpulence in females and lower relative weight of main viscerae in males), which should be considered for further preclinical studies and when even the current clinical application in women affected by PCOS or diabetes is implemented., The experimental work was supported by funds from the Ministry of Economy and competitiveness (project AGL2015-72198-EXP), co-funded by FEDER. MVG, CGC and AHM are backed by the Spanish Government (MVG: FPU National Program Grant Number FPU014/01285. CGC and AHM: FPI National Program Grant Number BES-2014-070464 and BES-2017-080541, respectively)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Maternal Metformin Treatment Improves Developmental and Metabolic Traits of IUGR Fetuses

  • Garcia-Contreras, Consolacion
  • Vázquez-Gómez, M.
  • Pesántez-Pacheco, José Luis
  • Torres-Rovira, L.
  • Heras-Molina, Ana
  • Encinas, Teresa
  • Astiz, Susana
  • González De Bulnes, Antonio
10 Pág., Metformin is an anti-hyperglycemic drug widely used for the treatment of insulin resistance and glucose intolerance and is currently considered for preventing large-for-gestational-age (LGA) offspring in pregnant women affected by obesity or diabetes. Our hypothesis was the opposite-metformin may be used for improving the development of offspring affected by intrauterine growth restriction (IUGR) and preventing the appearance of small-for-gestational-age (SGA) neonates in non-obese and non-diabetic but malnourished pregnancies. The current study, performed in a swine preclinical model of IUGR by undernutrition, showed that fetuses in the treated group showed no significant increases in body-weight, but showed a significantly higher weight of the brain, the total thoracic and abdominal viscera, the liver, the kidneys, the spleen, and the adrenal glands. Maternal metformin treatment was also related to significant increases in the fetal plasma concentration of parameters indicative of glycemic (glucose and fructosamine) and lipid profiles (triglycerides). Overall, these results suggest a protective effect of the treatment on the developmental competence of the fetuses. These findings may be of high value for human medicine in case of maternal malnutrition, since metformin is a cheap drug easily available, but also in case of placental deficiency, since metformin seems to improve placental development and function., The experimental work was supported by funds from the Ministry of Economy and competitiveness (project AGL2015-72198-EXP), co-funded by FEDER. M.V.-G., C.G.-C. and A.H.-M. are backed by the Spanish Government (M.V.-G.: FPU National Program Grant Number FPU014/01285. C.G.-C. and A.H.-M.: FPI National Program Grant Number BES-2014-070464 and BES-2017-080541, respectively)., Peer reviewed
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

The Effects of Maternal Metformin Treatment on Late Prenatal and Early Postnatal Development of the Offspring Are Modulated by Sex

  • García-Contreras, Consolación|||0000-0003-4624-2585
  • Vázquez-Gómez, Marta|||0000-0002-8916-2086
  • Pesántez-Pacheco, José Luis|||0000-0002-5669-6014
  • Heras-Molina, Ana|||0000-0001-7496-9680
  • Encinas, Teresa
  • Astiz, Susana|||0000-0002-9718-0903
  • Gonzalez-Bulnes, Antonio|||0000-0002-0917-4475
Metformin is currently used to improve pregnancy outcome in women affected by polycystic ovary syndrome (PCOS) or diabetes. However, metformin may also be useful in pregnancies at risk of intrauterine growth restriction (IUGR) since it improves placental efficiency and the fetuses' developmental competence. There is no data on the duration of the effect of this treatment from the prenatal up to the postnatal stages. Therefore, the present trial aimed at determining the impact of metformin treatment on the offspring neonatal traits and early postnatal development (i.e., during lactation) using an in vivo swine model. The results support that maternal metformin treatment during pregnancy induces protective changes in body shape and composition of the progeny (i.e., larger head size and body length at birth and higher total viscera weight at weaning). However, there were also major effects of the offspring sex (smaller corpulence in females and lower relative weight of main viscerae in males), which should be considered for further preclinical studies and when even the current clinical application in women affected by PCOS or diabetes is implemented.